A circulating inhibitor of fluid-phase amplification. C3 convertase formation in systemic lupus erythematosus.
Open Access
- 1 June 1985
- journal article
- research article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 75 (6) , 1786-1795
- https://doi.org/10.1172/jci111891
Abstract
C3 nephritic factor (C3NeF) was used to assess the formation of the fluid-phase amplification convertase, C3b,Bb, in 37 serum specimens from 24 patients with systemic lupus erythematosus (SLE). C3b,Bb formation was measured by the concentration of Ba, released when C3b,B is activated. Incubation of normal human serum (NHS) with C3NeF accelerates C3b amplification loop turnover with the formation of large quantities of C3b,Bb. In contrast, sera from 22 of 24 patients with SLE formed little or no convertase when incubated with C3NeF. C3 conversion to C3b was commensurately reduced. The inhibition could not be attributed to depressed serum concentrations of C3, factor B, or classical pathway components. Inhibitor present in excess could be demonstrated in 23 of 34 specimens of SLE serum by mixing experiments. The spontaneous convertase formation that occurs when a portion of the serum H is inactivated with F(ab')2 anti-H was also shown to be inhibited in SLE serum. The inhibition was found, however, to be H dependent in that convertase formation was normal in SLE serum depleted of H. It is concluded that the C3b in most SLE sera is unusually susceptible to inactivation by H, but a functional abnormality was not demonstrable in either C3 or H isolated from SLE serum. The inhibition could be simulated in NHS by addition of heparin, 100 micrograms/ml. In vivo, inhibition of convertase formation could interfere with the solubilization and disposal of immune complexes by reducing the deposition of C3b on the immune complex lattice.This publication has 36 references indexed in Scilit:
- C-reactive protein inhibits pneumococcal activation of the alternative pathway by increasing the interaction between factor H and C3b.The Journal of Immunology, 1984
- The Role of Complement in the Binding and Degradation of Immunoglobulin Aggregates by MacrophagesThe Journal of Immunology, 1979
- The Alternative Pathway C3/C5 Convertase: Chemical Basis of Factor B ActivationThe Journal of Immunology, 1979
- The effect of complement on the ingestion of soluble antigen-antibody complexes and IgM aggregates by mouse peritoneal macrophages.The Journal of Experimental Medicine, 1978
- Requirements for the solubilization of immune aggregates by complement. The role of the classical pathway.Journal of Clinical Investigation, 1978
- Complement C3 convertase: Cell surface restriction of β1H control and generation of restriction on neuraminidase-treated cellsProceedings of the National Academy of Sciences, 1978
- Regulation by membrane sialic acid of β1H-dependent decay-dissociation of amplification C3 convertase of the alternative complement pathwayProceedings of the National Academy of Sciences, 1978
- Human complement C3b inactivator: isolation, characterization, and demonstration of an absolute requirement for the serum protein beta1H for cleavage of C3b and C4b in solution.The Journal of Experimental Medicine, 1977
- Modulation of the alternative complement pathways by beta 1 H globulin.The Journal of Experimental Medicine, 1976
- Studies on the mechanism of solubilization of immune precipitates by serum.The Journal of Experimental Medicine, 1976